Novavax announces positive top-line data from phase I Ebola vaccine trial

Thursday, July 23, 2015

Novavax, a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, has announced positive top-line data from a phase I clinical trial of its Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M as part of the World Health Organization’s (WHO) Fifth Teleconference on Ebola Vaccine Clinical Trials. The trial demonstrated that the Ebola GP Vaccine was highly immunogenic, well-tolerated and, in conjunction with Novavax’ proprietary Matrix-M adjuvant, resulted in significant antigen dose-sparing. 

[Read More]

Novavax, PATH to produce vaccines for low-income countries

Monday, July 23, 2012

Novavax, a clinical-stage biopharmaceutical company based in Rockville, Md., has partnered with international non-profit organization PATH to develop a vaccine against respiratory syncytial virus (RSV) — the most common cause of childhood respiratory infection globally — for infants in low-income countries with a high disease burden.

[Read More]

Novavax appoints Stanley C. Erck as president and CEO

Wednesday, April 20, 2011

Novavax’s Stanley C. Erck, its former executive chairman, has been appointed to the position of president and chief executive officer and will remain as a member of the board of directors. Current board member James Young, Ph.D., will assume the position of chairman of the board.

[Read More]